Bellei Elisa, Monari Emanuela, Bergamini Stefania, Pini Luigi Alberto, Aldo Tomasi, Ozben Tomris
Department of Diagnostic Medicine, Clinic and Public Health, University of Modena and Reggio Emilia, Modena, Italy.
Headache and Drug Abuse Study Center, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
EJIFCC. 2018 Dec 5;29(4):290-297. eCollection 2018 Dec.
Urinary proteomics is primarily applied to the study of renal and urogenital tract disorders. Here are reported two distinct successful examples of this approach for the discovery of early urinary biomarkers of kidney-related dysfunctions: diabetic nephropathy (DN), a well-known complication of diabetes frequently leading to dialysis, and drug-induced nephrotoxicity, a possible condition caused by medication-overuse headache (MOH). Early detection of kidney disorders based on selective biomarkers could permit to diagnose patients at the initial stage of the disease, where the therapy may be suspended or prevent disease advancement.
Urine samples were first concentrated and desalted. Subsequently, they were subjected to two-dimensional gel electrophoresis (2-DE) coupled to mass spectrometry (MS) for protein identification. Furthermore, some proteins were verified by Western blot and ELISA test.
In diabetes-related study, 11 differentially expressed proteins were detected (8 up-regulated and 3 down-regulated) in type 2 diabetic (T2D) and T2DN patients compared to the healthy control subjects. In the MOH study, a total of 21 over-excreted proteins were revealed in urine of non-steroidal anti-inflammatory drugs (NSAIDs) and mixtures abusers vs controls. Particularly, 4 proteins were positively validated by immunob-lotting and EUSA.
Urinary proteomics allows non-invasive assessment of renal diseases at an early stage by the identification of characteristic protein pattern.
尿液蛋白质组学主要应用于肾脏和泌尿生殖道疾病的研究。本文报道了该方法在发现肾脏相关功能障碍早期尿液生物标志物方面的两个不同的成功实例:糖尿病肾病(DN),这是糖尿病常见的并发症,常导致透析;以及药物性肾毒性,这是一种可能由药物过量使用性头痛(MOH)引起的病症。基于选择性生物标志物早期检测肾脏疾病,能够在疾病初期诊断患者,此时治疗可能暂停或预防疾病进展。
首先对尿液样本进行浓缩和脱盐。随后,将其进行二维凝胶电泳(2-DE)并结合质谱(MS)以鉴定蛋白质。此外,一些蛋白质通过蛋白质印迹法和酶联免疫吸附测定(ELISA)试验进行验证。
在糖尿病相关研究中,与健康对照受试者相比,在2型糖尿病(T2D)和T2DN患者中检测到11种差异表达蛋白质(8种上调和3种下调)。在MOH研究中,与对照组相比,在非甾体抗炎药(NSAIDs)和混合药物滥用者的尿液中总共发现了21种过度排泄的蛋白质。特别地,4种蛋白质通过免疫印迹法和酶联免疫吸附测定得到了阳性验证。
尿液蛋白质组学通过识别特征性蛋白质模式,能够在早期对肾脏疾病进行非侵入性评估。